BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Oda Y, Hamaoka N, Hiroi T, Imaoka S, Hase I, Tanaka K, Funae Y, Ishizaki T, Asada A. Involvement of human liver cytochrome P4502B6 in the metabolism of propofol. Br J Clin Pharmacol. 2001;51:281-285. [PMID: 11298076 DOI: 10.1046/j.1365-2125.2001.00344.x] [Cited by in Crossref: 75] [Cited by in F6Publishing: 67] [Article Influence: 3.8] [Reference Citation Analysis]
Number Citing Articles
1 Jones BC, Middleton DS, Youdim K. 6 Cytochrome P450 Metabolism and Inhibition: Analysis for Drug Discovery. Progress in Medicinal Chemistry Volume 47. Elsevier; 2009. pp. 239-63. [DOI: 10.1016/s0079-6468(08)00206-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Hedrich WD, Hassan HE, Wang H. Insights into CYP2B6-mediated drug-drug interactions. Acta Pharm Sin B 2016;6:413-25. [PMID: 27709010 DOI: 10.1016/j.apsb.2016.07.016] [Cited by in Crossref: 62] [Cited by in F6Publishing: 53] [Article Influence: 12.4] [Reference Citation Analysis]
3 Santos CHMD, Gomes OM, Pontes JCDV, Miiji LNO, Higa EI. Uso do propofol (2,6 diisopropilfenol) como inibidor da lesão tecidual na isquemia e reperfusão mesentérica: estudo experimental em ratos. Acta Cir Bras 2003;18:347-54. [DOI: 10.1590/s0102-86502003000400016] [Cited by in Crossref: 7] [Article Influence: 0.4] [Reference Citation Analysis]
4 Walsky RL, Obach RS. Measurement of in vitro cytochrome P450 2B6 activity. Curr Protoc Toxicol 2009;Chapter 4:Unit4.27. [PMID: 23045012 DOI: 10.1002/0471140856.tx0427s39] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
5 Kirchheiner J, Klein C, Meineke I, Sasse J, Zanger UM, Mürdter TE, Roots I, Brockmöller J. Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. Pharmacogenetics. 2003;13:619-626. [PMID: 14515060 DOI: 10.1097/00008571-200310000-00005] [Cited by in Crossref: 186] [Cited by in F6Publishing: 166] [Article Influence: 10.9] [Reference Citation Analysis]
6 Kanazawa H, Okada A, Igarashi E, Higaki M, Miyabe T, Sano T, Nishimura R. Determination of midazolam and its metabolite as a probe for cytochrome P450 3A4 phenotype by liquid chromatography–mass spectrometry. Journal of Chromatography A 2004;1031:213-8. [DOI: 10.1016/j.chroma.2003.12.039] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 1.6] [Reference Citation Analysis]
7 Jun MR, Kim MG, Han KS, Park JE, Cho HB, Park SY, Song S, Yoo JH, Chung JW, Kim SH. Potency of propofol for inducing loss of consciousness in end-stage kidney disease patients. PLoS One 2021;16:e0254520. [PMID: 34383773 DOI: 10.1371/journal.pone.0254520] [Reference Citation Analysis]
8 Osaka Y, Inomata S, Tanaka E, Nakamura T, Honda K, Miyabe M, Toyooka H, Tanaka M. Effect of propofol on ropivacaine metabolism in human liver microsomes. J Anesth 2006;20:60-3. [DOI: 10.1007/s00540-005-0358-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
9 Allegaert K, Vancraeynest J, Rayyan M, de Hoon J, Cossey V, Naulaers G, Verbesselt R. Urinary propofol metabolites in early life after single intravenous bolus. British Journal of Anaesthesia 2008;101:827-31. [DOI: 10.1093/bja/aen276] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
10 Kneiseler G, Bachmann HS, Bechmann LP, Dechene A, Heyer T, Baba H, Saner F, Jochum C, Gerken G, Canbay A. A Rare Case of Propofol-Induced Acute Liver Failure and Literature Review. Case Rep Gastroenterol 2010;4:57-65. [PMID: 21103229 DOI: 10.1159/000262448] [Cited by in Crossref: 24] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
11 Doyle A, Wilkinson D. Day case general anaesthesia in a patient with narcolepsy. Anaesthesia 2008;63:880-2. [DOI: 10.1111/j.1365-2044.2008.05501.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
12 Asimus S, Ashton M. Artemisinin--a possible CYP2B6 probe substrate? Biopharm Drug Dispos 2009;30:265-75. [PMID: 19562679 DOI: 10.1002/bdd.665] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
13 Asha S, Vidyavathi M. Role of Human Liver Microsomes in In Vitro Metabolism of Drugs—A Review. Appl Biochem Biotechnol 2010;160:1699-722. [DOI: 10.1007/s12010-009-8689-6] [Cited by in Crossref: 86] [Cited by in F6Publishing: 76] [Article Influence: 7.2] [Reference Citation Analysis]
14 Ingelman-Sundberg M. Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms. Naunyn Schmiedebergs Arch Pharmacol 2004;369:89-104. [PMID: 14574440 DOI: 10.1007/s00210-003-0819-z] [Cited by in Crossref: 210] [Cited by in F6Publishing: 179] [Article Influence: 11.7] [Reference Citation Analysis]
15 Zanger UM, Klein K. Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevance. Front Genet. 2013;4:24. [PMID: 23467454 DOI: 10.3389/fgene.2013.00024] [Cited by in Crossref: 178] [Cited by in F6Publishing: 136] [Article Influence: 22.3] [Reference Citation Analysis]
16 Lejus C, Fautrel A, Mallédant Y, Guillouzo A. Inhibition of cytochrome P450 2E1 by propofol in human and porcine liver microsomes. Biochem Pharmacol 2002;64:1151-6. [PMID: 12234619 DOI: 10.1016/s0006-2952(02)01226-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 1] [Article Influence: 0.9] [Reference Citation Analysis]
17 Croom EL, Stevens JC, Hines RN, Wallace AD, Hodgson E. Human hepatic CYP2B6 developmental expression: The impact of age and genotype. Biochemical Pharmacology 2009;78:184-90. [DOI: 10.1016/j.bcp.2009.03.029] [Cited by in Crossref: 68] [Cited by in F6Publishing: 64] [Article Influence: 5.7] [Reference Citation Analysis]
18 Chan W, Chen T, Chen R, Sun W, Ueng T. Propofol metabolism is enhanced after repetitive ketamine administration in rats: the role of cytochrome P-450 2B induction. British Journal of Anaesthesia 2006;97:351-8. [DOI: 10.1093/bja/ael173] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
19 Gelboin HV, Krausz K. Monoclonal Antibodies and Multifunctional Cytochrome P450: Drug Metabolism as Paradigm. The Journal of Clinical Pharmacology 2006;46:353-72. [DOI: 10.1177/0091270005285200] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
20 Wang H, Tompkins LM. CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme. Curr Drug Metab. 2008;9:598-610. [PMID: 18781911 DOI: 10.2174/138920008785821710] [Cited by in Crossref: 219] [Cited by in F6Publishing: 207] [Article Influence: 16.8] [Reference Citation Analysis]
21 Tai YT, Lin YL, Chang CC, Cherng YG, Don MJ, Chen RM. Ring-oxidative biotransformation and drug interactions of propofol in the livers of rats. Biomed Res Int 2015;2015:658928. [PMID: 25710017 DOI: 10.1155/2015/658928] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
22 Klein K, Lang T, Saussele T, Barbosa-Sicard E, Schunck WH, Eichelbaum M, Schwab M, Zanger UM. Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz. Pharmacogenet Genomics. 2005;15:861-873. [PMID: 16272958 DOI: 10.1097/01213011-200512000-00004] [Cited by in Crossref: 183] [Cited by in F6Publishing: 169] [Article Influence: 12.2] [Reference Citation Analysis]
23 Palacharla RC, Nirogi R, Uthukam V, Manoharan A, Ponnamaneni RK, Kalaikadhiban I. Quantitative in vitro phenotyping and prediction of drug interaction potential of CYP2B6 substrates as victims. Xenobiotica 2018;48:663-75. [PMID: 28737446 DOI: 10.1080/00498254.2017.1354267] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
24 Niu RJ, Zheng QC, Zhang JL, Zhang HX. Analysis of clinically relevant substrates of CYP2B6 enzyme by computational methods. J Mol Model 2011;17:2839-46. [PMID: 21301907 DOI: 10.1007/s00894-011-0970-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
25 Regensburger M, Huttner HB, Doerfler A, Schwab S, Staykov D. Propofol-related urine discoloration in a patient with fatal atypical intracerebral hemorrhage treated with hypothermia. Springerplus 2014;3:551. [PMID: 25332856 DOI: 10.1186/2193-1801-3-551] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
26 Shioya N, Ishibe Y, Shibata S, Makabe H, Kan S, Matsumoto N, Takahashi G, Yamada Y, Endo S. Green Urine Discoloration due to Propofol Infusion: A Case Report. Case Rep Emerg Med 2011;2011:242514. [PMID: 23326690 DOI: 10.1155/2011/242514] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
27 Kim JH, Choi SM, Shreatha R, Jeong GS, Jeong TC, Lee S. Deoxyshikonin reversibly inhibits cytochrome P450 2B6. Biopharm Drug Dispos 2020;41:221-5. [PMID: 32364297 DOI: 10.1002/bdd.2230] [Reference Citation Analysis]
28 Pelkonen O, Turpeinen M, Hakkola J, Honkakoski P, Hukkanen J, Raunio H. Inhibition and induction of human cytochrome P450 enzymes: current status. Arch Toxicol. 2008;82:667-715. [PMID: 18618097 DOI: 10.1007/s00204-008-0332-8] [Cited by in Crossref: 356] [Cited by in F6Publishing: 317] [Article Influence: 27.4] [Reference Citation Analysis]
29 Pascoe PJ, Ilkiw JE, Frischmeyer KJ. The effect of the duration of propofol administration on recovery from anesthesia in cats. Veterinary Anaesthesia and Analgesia 2006;33:2-7. [DOI: 10.1111/j.1467-2995.2005.00216.x] [Cited by in Crossref: 65] [Cited by in F6Publishing: 43] [Article Influence: 4.3] [Reference Citation Analysis]
30 Hiraoka H, Yamamoto K, Miyoshi S, Morita T, Nakamura K, Kadoi Y, Kunimoto F, Horiuchi R. Kidneys contribute to the extrahepatic clearance of propofol in humans, but not lungs and brain. Br J Clin Pharmacol 2005;60:176-82. [PMID: 16042671 DOI: 10.1111/j.1365-2125.2005.02393.x] [Cited by in Crossref: 84] [Cited by in F6Publishing: 68] [Article Influence: 5.6] [Reference Citation Analysis]
31 Yang LQ, Yu WF, Cao YF, Gong B, Chang Q, Yang GS. Potential inhibition of cytochrome P450 3A4 by propofol in human primary hepatocytes. World J Gastroenterol 2003; 9(9): 1959-1962 [PMID: 12970884 DOI: 10.3748/wjg.v9.i9.1959] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
32 Bodnar J. The Use of Propofol for Continuous Deep Sedation at the End of Life: A Definitive Guide. Journal of Pain & Palliative Care Pharmacotherapy 2019;33:63-81. [DOI: 10.1080/15360288.2019.1667941] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
33 Al-Jahdari WS, Yamamoto K, Hiraoka H, Nakamura K, Goto F, Horiuchi R. Prediction of total propofol clearance based on enzyme activities in microsomes from human kidney and liver. Eur J Clin Pharmacol 2006;62:527-33. [PMID: 16763826 DOI: 10.1007/s00228-006-0130-2] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 2.1] [Reference Citation Analysis]
34 Zanger UM, Fischer J, Klein K, Lang T. Detection of single nucleotide polymorphisms in CYP2B6 gene. Methods Enzymol 2002;357:45-53. [PMID: 12424896 DOI: 10.1016/s0076-6879(02)57664-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
35 Ouchi K, Sugiyama K. Required propofol dose for anesthesia and time to emerge are affected by the use of antiepileptics: prospective cohort study. BMC Anesthesiol 2015;15:34. [PMID: 25788855 DOI: 10.1186/s12871-015-0006-z] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
36 Saari TI, Olkkola KT. Azole antimycotics and drug interactions in the perioperative period. Curr Opin Anaesthesiol 2010;23:441-8. [PMID: 20610983 DOI: 10.1097/ACO.0b013e32833a254d] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
37 Tanaka E, Takano Y, Inomata S, Toyooka H, Honda K. Premedication medicines do not cause drug metabolic interaction with propofol using human liver microsomes in vitro. Eur J Clin Pharmacol 2004;60:565-8. [PMID: 15351923 DOI: 10.1007/s00228-004-0807-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
38 Xie HJ, Yasar U, Lundgren S, Griskevicius L, Terelius Y, Hassan M, Rane A. Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation. Pharmacogenomics J 2003;3:53-61. [PMID: 12629583 DOI: 10.1038/sj.tpj.6500157] [Cited by in Crossref: 142] [Cited by in F6Publishing: 136] [Article Influence: 7.9] [Reference Citation Analysis]
39 Loryan I, Lindqvist M, Johansson I, Hiratsuka M, van der Heiden I, van Schaik RH, Jakobsson J, Ingelman-sundberg M. Influence of sex on propofol metabolism, a pilot study: implications for propofol anesthesia. Eur J Clin Pharmacol 2012;68:397-406. [DOI: 10.1007/s00228-011-1132-2] [Cited by in Crossref: 38] [Cited by in F6Publishing: 27] [Article Influence: 3.8] [Reference Citation Analysis]
40 Gill KL, Gertz M, Houston JB, Galetin A. Application of a physiologically based pharmacokinetic model to assess propofol hepatic and renal glucuronidation in isolation: utility of in vitro and in vivo data. Drug Metab Dispos 2013;41:744-53. [PMID: 23303442 DOI: 10.1124/dmd.112.050294] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
41 Turpeinen M, Nieminen R, Juntunen T, Taavitsainen P, Raunio H, Pelkonen O. SELECTIVE INHIBITION OF CYP2B6-CATALYZED BUPROPION HYDROXYLATION IN HUMAN LIVER MICROSOMES IN VITRO. Drug Metab Dispos 2004;32:626-31. [DOI: 10.1124/dmd.32.6.626] [Cited by in Crossref: 77] [Cited by in F6Publishing: 70] [Article Influence: 4.5] [Reference Citation Analysis]
42 Ouchi K. Intravenous General Anesthesia for Patients with Neurological Disorders. Glob J Anesth 2014. [DOI: 10.17352/2455-3476.000018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
43 Jacobsen JK, Jensen B, Skonberg C, Hansen SH, Badolo L. Time-course activities of Oct1, Mrp3, and cytochrome P450s in cultures of cryopreserved rat hepatocytes. European Journal of Pharmaceutical Sciences 2011;44:427-36. [DOI: 10.1016/j.ejps.2011.09.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
44 Bumpus NN, Sridar C, Kent UM, Hollenberg PF. THE NATURALLY OCCURRING CYTOCHROME P450 (P450) 2B6 K262R MUTANT OF P450 2B6 EXHIBITS ALTERATIONS IN SUBSTRATE METABOLISM AND INACTIVATION. Drug Metab Dispos 2005;33:795-802. [DOI: 10.1124/dmd.105.003749] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 1.9] [Reference Citation Analysis]
45 Ho C, Hayes D Jr, Khosravi M, Splaingard ML, Tumin D, Lloyd EA. Sedation with Propofol for Bronchoscopy in Cystic Fibrosis Lung Transplant Recipients. Lung 2018;196:435-9. [PMID: 29797070 DOI: 10.1007/s00408-018-0119-5] [Reference Citation Analysis]
46 Eleveld DJ. Propofol PK-PD. In: Absalom AR, Mason KP, editors. Total Intravenous Anesthesia and Target Controlled Infusions. Cham: Springer International Publishing; 2017. pp. 191-208. [DOI: 10.1007/978-3-319-47609-4_11] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
47 Polsky-Fisher SL, Cao H, Lu P, Gibson CR. Effect of cytochromes P450 chemical inhibitors and monoclonal antibodies on human liver microsomal esterase activity. Drug Metab Dispos 2006;34:1361-6. [PMID: 16720683 DOI: 10.1124/dmd.106.009704] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
48 Kim K, Chung J, Jung D, Park J. Identification of cytochrome P450 isoforms involved in the metabolism of loperamide in human liver microsomes. Eur J Clin Pharmacol 2004;60:575-81. [DOI: 10.1007/s00228-004-0815-3] [Cited by in Crossref: 60] [Cited by in F6Publishing: 54] [Article Influence: 3.5] [Reference Citation Analysis]
49 Cohen M, Sadhasivam S, Vinks AA. Pharmacogenetics in perioperative medicine. Current Opinion in Anaesthesiology 2012;25:419-27. [DOI: 10.1097/aco.0b013e3283556129] [Cited by in Crossref: 47] [Cited by in F6Publishing: 10] [Article Influence: 5.2] [Reference Citation Analysis]
50 Dinis-Oliveira RJ. Metabolic Profiles of Propofol and Fospropofol: Clinical and Forensic Interpretative Aspects. Biomed Res Int 2018;2018:6852857. [PMID: 29992157 DOI: 10.1155/2018/6852857] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 7.3] [Reference Citation Analysis]
51 Toselli F, Dodd PR, Gillam EMJ. Emerging roles for brain drug-metabolizing cytochrome P450 enzymes in neuropsychiatric conditions and responses to drugs. Drug Metabolism Reviews 2016;48:379-404. [DOI: 10.1080/03602532.2016.1221960] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 3.4] [Reference Citation Analysis]
52 Lichtenbelt B, Mertens M, Vuyk J. Strategies to Optimise Propofol-Opioid Anaesthesia: . Clinical Pharmacokinetics 2004;43:577-93. [DOI: 10.2165/00003088-200443090-00002] [Cited by in Crossref: 45] [Cited by in F6Publishing: 33] [Article Influence: 2.6] [Reference Citation Analysis]
53 Wilhelm W, Buchinger H, Biedler A, Altmann S, Larsen R, Kreuer S. Einfluss des Geschlechts auf Propofolverbrauch und Aufwachzeiten bei standardisierter Anästhesietiefe. Anaesthesist 2005;54:567-74. [DOI: 10.1007/s00101-005-0836-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
54 Campos SP, de Lurdes Pinto M, Gomes G, de Pinho PG, Monteiro JA, Félix LM, Branco PS, Ferreira LM, Antunes LM. Expression of CYP1A1 and CYP1A2 in the liver and kidney of rabbits after prolonged infusion of propofol. Experimental and Toxicologic Pathology 2016;68:521-31. [DOI: 10.1016/j.etp.2016.07.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
55 Wang H, Faucette S, Sueyoshi T, Moore R, Ferguson S, Negishi M, LeCluyse EL. A novel distal enhancer module regulated by pregnane X receptor/constitutive androstane receptor is essential for the maximal induction of CYP2B6 gene expression. J Biol Chem 2003;278:14146-52. [PMID: 12571232 DOI: 10.1074/jbc.M212482200] [Cited by in Crossref: 166] [Cited by in F6Publishing: 83] [Article Influence: 9.2] [Reference Citation Analysis]
56 Yamazaki H, Shimizu M, Nagashima T, Minoshima M, Murayama N. Rat Cytochrome P450 2C11 in Liver Microsomes Involved in Oxidation of Anesthetic Agent Propofol and Deactivated by Prior Treatment with Propofol. Drug Metab Dispos 2006;34:1803-5. [DOI: 10.1124/dmd.106.011627] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
57 Moore GD, Walker AM, MacLaren R. Fospropofol: a new sedative-hypnotic agent for monitored anesthesia care. Ann Pharmacother. 2009;43:1802-1808. [PMID: 19826098 DOI: 10.1345/aph.1m290] [Cited by in Crossref: 22] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
58 Hasselstrøm J, Linnet K. IN VITRO STUDIES ON QUETIAPINE METABOLISM USING THE SUBSTRATE DEPLETION APPROACH WITH FOCUS ON DRUG-DRUG INTERACTIONS. Drug Metabolism and Drug Interactions 2006;21. [DOI: 10.1515/dmdi.2006.21.3-4.187] [Cited by in Crossref: 14] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
59 Ominami M, Nagami Y, Shiba M, Tominaga K, Sakai T, Maruyama H, Kato K, Minamino H, Fukunaga S, Tanaka F, Sugimori S, Kamata N, Machida H, Yamagami H, Tanigawa T, Watanabe T, Fujiwara Y, Arakawa T. Comparison of propofol with midazolam in endoscopic submucosal dissection for esophageal squamous cell carcinoma: a randomized controlled trial. J Gastroenterol 2018;53:397-406. [DOI: 10.1007/s00535-017-1358-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
60 Michelet R, Van Bocxlaer J, Allegaert K, Vermeulen A. The use of PBPK modeling across the pediatric age range using propofol as a case. J Pharmacokinet Pharmacodyn 2018;45:765-85. [PMID: 30298439 DOI: 10.1007/s10928-018-9607-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
61 Mourão AL, de Abreu FG, Fiegenbaum M. Impact of the Cytochrome P450 2B6 (CYP2B6) Gene Polymorphism c.516G>T (rs3745274) on Propofol Dose Variability. Eur J Drug Metab Pharmacokinet 2016;41:511-5. [PMID: 26141406 DOI: 10.1007/s13318-015-0289-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
62 Restrepo JG, Martínez C, García-Agúndez A, Gaviria E, Laguna JJ, García-Martín E, Agúndez JA. Cytochrome P450 CYP2B6 genotypes and haplotypes in a Colombian population: identification of novel variant CYP2B6 alleles. Pharmacogenet Genomics 2011;21:773-8. [PMID: 21886015 DOI: 10.1097/FPC.0b013e32834b3efc] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
63 Meyer MR, Maurer HH. Absorption, distribution, metabolism and excretion pharmacogenomics of drugs of abuse. Pharmacogenomics 2011;12:215-33. [DOI: 10.2217/pgs.10.171] [Cited by in Crossref: 63] [Cited by in F6Publishing: 44] [Article Influence: 6.3] [Reference Citation Analysis]
64 Zhou SF, Liu JP, Chowbay B. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev. 2009;41:89-295. [PMID: 19514967 DOI: 10.1080/03602530902843483] [Cited by in Crossref: 475] [Cited by in F6Publishing: 404] [Article Influence: 39.6] [Reference Citation Analysis]
65 Murayama N, Minoshima M, Shimizu M, Guengerich FP, Yamazaki H. Involvement of human cytochrome P450 2B6 in the ω - and 4-hydroxylation of the anesthetic agent propofol. Xenobiotica 2008;37:717-24. [DOI: 10.1080/00498250701449431] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
66 Smits A, De Cock RF, Cossey V, Knibbe CA, Allegaert K. Is indirect hyperbilirubinemia a useful biomarker of reduced propofol clearance in neonates? Biomark Med 2012;6:283-9. [PMID: 22731901 DOI: 10.2217/bmm.12.25] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
67 Miksys S, Tyndale RF. The Unique Regulation of Brain Cytochrome P450 2 (CYP2) Family Enzymes by Drugs and Genetics. Drug Metabolism Reviews 2004;36:313-33. [DOI: 10.1081/dmr-120034149] [Cited by in Crossref: 99] [Cited by in F6Publishing: 27] [Article Influence: 5.8] [Reference Citation Analysis]